Rakuten Securities Inc. Increases Stock Holdings in Stryker Co. (NYSE:SYK)

Rakuten Securities Inc. boosted its position in shares of Stryker Co. (NYSE:SYK) by 618.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 79 shares of the medical technology company’s stock after acquiring an additional 68 shares during the quarter. Rakuten Securities Inc.’s holdings in Stryker were worth $28,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker in the 4th quarter valued at about $25,000. Dunhill Financial LLC boosted its stake in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Centricity Wealth Management LLC purchased a new position in shares of Stryker in the 4th quarter valued at about $30,000. BankPlus Trust Department purchased a new position in shares of Stryker in the 4th quarter valued at about $33,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Stryker in the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.0 %

NYSE:SYK opened at $363.79 on Friday. The firm has a market cap of $138.81 billion, a P/E ratio of 46.88, a PEG ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The stock’s 50 day simple moving average is $382.87 and its 200-day simple moving average is $373.26. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 EPS. Equities analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Activity

In related news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on SYK. Argus set a $450.00 price objective on Stryker in a research note on Monday, February 3rd. JMP Securities reissued a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Stifel Nicolaus raised their target price on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.